Literature DB >> 3117086

Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

H Halila1, M L Huhtala, C Haglund, S Nordling, U H Stenman.   

Abstract

The levels of tumour-associated trypsin inhibitor (TATI), CA 125 and CEA were measured in ovarian cyst fluids from 21 patients. TATI in cyst fluid was immunologically and physicochemically similar to the peptide originally isolated from the urine of a patient with ovarian cancer. Mucinous cysts contained significantly higher levels of TATI than did serous cysts. Immunohistochemically TATI was localized in the apical parts of cells of mucinous ovarian cysts. These results suggest that this tumour-associated peptide is actually produced by a tumour. Like TATI, CEA occurred at higher concentrations in mucinous than in serous cyst fluids, whereas CA 125 was found in higher concentrations in serous than in mucinous cyst fluids. The concentrations of these tumours markers in cyst fluids did not correlate with circulating levels of the same markers. In spite of the very high levels of all these tumour markers in benign cyst fluids, serum levels were normal or only slightly elevated. Clearly elevated serum levels occurred only in patients with malignant tumours. Cyst fluid levels of these tumour markers could not be used to distinguish between benign and malignant tumours.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117086      PMCID: PMC2002139          DOI: 10.1038/bjc.1987.175

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  [On protease inhibitors, V. On the chemistry and physiology of the specific trypsin inhibitors from the ox, dog, pig and human pancreas].

Authors:  H Fritz; I Hüller; M Wiedemann; E Werle
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1967-04

Review 2.  Tumor invasion and the extracellular matrix.

Authors:  L A Liotta; C N Rao; S H Barsky
Journal:  Lab Invest       Date:  1983-12       Impact factor: 5.662

3.  A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms.

Authors:  J R van Nagell; Q A Pletsch; D M Goldenberg
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

4.  Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer.

Authors:  M L Huhtala; K Pesonen; N Kalkkinen; U H Stenman
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

5.  Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy.

Authors:  M L Huhtala; K Kahanpää; M Seppälä; H Halila; U H Stenman
Journal:  Int J Cancer       Date:  1983-06-15       Impact factor: 7.396

6.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

7.  Immunochemical demonstration of an ovarian cancer-associated urinary peptide.

Authors:  U H Stenman; M L Huhtala; R Koistinen; M Seppälä
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

8.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

9.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

10.  Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.

Authors:  C Haglund; M L Huhtala; H Halila; S Nordling; P J Roberts; T M Scheinin; U H Stenman
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

View more
  10 in total

1.  Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion.

Authors:  U Turpeinen; E Koivunen; U H Stenman
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

2.  Pancreatic secretory trypsin inhibitor in human Brunner's glands.

Authors:  H Bohe; M Bohe; C Lindström; K Ohlsson
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

3.  Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.

Authors:  O Mogensen; B Mogensen; A Jakobsen
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

4.  Expression of pancreatic secretory trypsin inhibitor (PSTI) in colorectal cancer.

Authors:  M Higashiyama; T Monden; N Tomita; M Murotani; Y Kawasaki; H Morimoto; A Murata; T Shimano; M Ogawa; T Mori
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

5.  Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery.

Authors:  Barbara Buonomo; Stefania A Noli; Alessandra Santini; Carlo Alviggi; Fedro A Peccatori
Journal:  Ecancermedicalscience       Date:  2019-11-26

6.  Urinary Biomarkers for Detection of Clinical Endometriosis or Adenomyosis.

Authors:  Wei-Chun Chen; Chao-Min Cheng; Wan-Ting Liao; Ting-Chang Chang
Journal:  Biomedicines       Date:  2022-04-01

7.  Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.

Authors:  H Halila; P Lehtovirta; U H Stenman
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.

Authors:  A P Wilson; H Fox; I V Scott; H Lee; M Dent; P R Golding
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

9.  TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.

Authors:  M Medl; E Ogris; C Peters-Engl; S Leodolter
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

10.  Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.

Authors:  Christine Mehner; Erin Miller; Alexandra Hockla; Mathew Coban; S John Weroha; Derek C Radisky; Evette S Radisky
Journal:  Oncogene       Date:  2020-09-14       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.